Cornerstone regains rights to technology from MedImmune
This article was originally published in Scrip
Executive Summary
Cornerstone Therapeutics has reacquired all development and commercial rights to technology related to its high-mobility group box protein 1 (HMGB1) from MedImmune, and is looking for a new partner to take the programme forward.